Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE).

Lonodelestat (POL6014) significantly and efficiently reduced the inflammatory processes of ALI in HNE treated mice[1]. Lonodelestat (POL6014, 0.1, 0.5, 2 and 10 mg/kg, intranasally administered) dose-dependently and significantly reduces the number of macrophages, epithelial cells, neutrophils and lymphocytes recovered in BAL. The maximum inhibition was reached at 2 mg/kg in reducing neutrophils by 65% (p<0.001), epithelial cells by 68% (p<0.001), macrophages by 33% (p<0.001) and lymphocytes by 77% (p<0.001)[1]. Animal Model: Ten-week-old male C57BL/6j mice[1]. Dosage: 0.05, 0.2, 0.5 and 5 mg/kg. Administration: Administered intranasally (i.n.) 15 minutes before HNE (30 UI, i.n.). Result: Reduced the inflammatory processes of ALI in HNE treated mice.